STATUS AND ENTITY

OVERVIEW OF AMENDMENTS & REMARKS

1999 NOV -5 PM 2: 46

\$2111

- 1. SPECIFICATION: No amendments.
- 2. CLAIM CANCELLATION DUE TO RESTRICTION REQUIREMENT: Non-elected prior claims 11 34, and 36 50 of record under traverse have been canceled. See "SUPPLEMENTAL REQUEST FOR RECONSIDERATION OF RESTRICTION REQUIREMENT UNDER 37 CFR 1.143" mailed June 26, 1998 enclosed.
- 3. CLAIM AMENDMENTS: Prior claims of record 2, 3, 35, and 51.
- 4. FEE STATUS: (small entity) A total of \$2785 has been paid on the present application which results in an overpayment of \$2111 per this PRELIMINARY AMENDMENT C which now presents (6) independent claims, and (10) dependent claims for a total of (16) claims.

BASIC NATIONAL FEE		\$350
EXCESS CLAIM FEES PREVIOUSLY PAID:		\$2435
EXCESS CLAIM FEES NOW Dindependent claims in excess of three: claims in excess of twenty: multiple dependent claims:	OUE: 3 x \$41 = \$123 6 x \$11 = \$66 \$135	\$324
OVERPAYMENT OF EXCESS CLAIM FEES		\$2111

REQUEST FOR REFUND OF OVERPAYMENT

5.

CLAIM AMENDMENTS

STATUS AND ENTITY BRANCH

Cancel the prior substitute and rewritten claims 11 -234, and 36 - 50 of record without prejudice, and without disclaimer of the subject matter involved under traverse of restriction requirement.

Remaining claims 1 - 10, 35, and 51 - 55 are now presented for examination as follows:

No amendment of claim 1 of record:

1. A method of treating deep tissue, or systemic fungal diseases comprising: administration to an area of disease a suitable carrier containing a primary anti-infective compound obtainable from capsicum pepper,

Amend claims 2 & 3 of record as follows:

or an equivalent in a therapeutically effective amount.

- 2. A method of treating systemic <u>fungal</u> diseases selected from the group consisting of blastomycosis, coccidioidomycosis, entomophthoromycosis, or paracoccidioidomycosis comprising: administration to an area of disease a suitable carrier containing a primary anti-infective agent obtainable from pepper, or an equivalent in a therapeutically effective amount.
- 3. A method of treating systemic <u>fungal</u> diseases selected from the group consisting of aspergillosis, candidiasis, cryptococcosis, or histoplasmosis comprising: